GURU.Markets stock price, segment price, and overall market index valuation
The company's share price VCNX
Vaccinex is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. Its share price reflects the high volatility and risks associated with its scientific platform and clinical trial results.
Share prices of companies in the market segment - Oncology immuno-therapy
Vaccinex is a biotech company developing antibody-based therapies for the treatment of cancer and neurodegenerative diseases, such as Huntington's disease. We've categorized it as an "Immuno-Oncology" company. The chart below shows how investors evaluate new approaches in these areas.
Broad Market Index - GURU.Markets
Vaccinex is a biotech company developing antibody-based therapies for the treatment of oncology and neurodegenerative diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Vaccinex shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VCNX - Daily change in the company's share price VCNX
Vaccinex, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its oncology and neuroscience drugs.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Vaccinex is a biopharmaceutical company developing antibodies to treat cancer and neurodegenerative diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing VCNX stock price movements.
Daily change in the price of a broad market stock, index - GURU.Markets
Vaccinex is a biotech company developing drugs to treat cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization VCNX
Vaccinex, Inc.'s year-to-date performance is a story about the development of its antibody-based drugs. Its 12-month market cap is entirely dependent on clinical trial data. The success of its lead candidate, which is being studied for Alzheimer's and Huntington's, could be a breakthrough in the treatment of these severe neurodegenerative diseases.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
As an early-stage biotech, Vaccinex is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunotherapy. Its stock price will reflect investors' speculative faith in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vaccinex is a biotech company whose value is locked into its scientific platform. Its shares move with news about clinical trials, not economic cycles. A sharp rise or fall amid a calm market is clear evidence that investors are betting on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization VCNX
Vaccinex is a clinical-stage biotech company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its drugs for the treatment of oncological and neurodegenerative diseases is the main driver.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Vaccinex is a clinical-stage biotech company developing antibody-based therapies for the treatment of cancer and neurodegenerative diseases such as Huntington's disease. The chart below shows the overall dynamics of the biotech sector, where platform technologies can be applied to treat various diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vaccinex is a clinical-stage biotech company developing drugs for the treatment of cancer and neurodegenerative diseases. Its shares are a venture bet on the success of scientific research. Their price is driven by news from the lab and is unrelated to the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization VCNX
Vaccinex, Inc., a clinical-stage biotech developing antibody-based therapies for oncology and neurodegenerative diseases, is experiencing high volatility. Weekly stock performance is driven by clinical trial news, reflecting the high stakes in these complex areas.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Vaccinex and the entire oncology biotech sector are riding the wave of industry-wide news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart shows how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Vaccinex is a biotech company developing antibody-based therapies. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that VCNX's performance is largely uncorrelated with the market, moving on its own unique news.
Market capitalization of the company, segment and market as a whole
VCNX - Market capitalization of the company VCNX
The Vaccinex chart is a financial map of antibody-based drug discovery. This biotech company's market cap reflects the hopes of its platform for discovering antibodies to treat cancer and neurodegenerative diseases. Its volatility reflects the complex and risky research in the most advanced fields of medicine.
VCNX - Share of the company's market capitalization VCNX within the market segment - Oncology immuno-therapy
Vaccinex's market capitalization in the immuno-oncology segment reflects investor sentiment toward its innovative approach to treating cancer and neurodegenerative diseases. The company's market capitalization reflects the potential of its antibody platform to create breakthrough therapies that can change patients' lives.
Market capitalization of the market segment - Oncology immuno-therapy
Vaccinex develops antibody-based drugs for the treatment of cancer and neurodegenerative diseases. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' faith in the potential of targeted therapies to combat the most complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vaccinex is a clinical-stage biotech company whose platform targets cancer and neurodegenerative diseases. Its market capitalization is a financial bet on a scientific hypothesis. Its value reflects investors' faith in the potential of their unique approach to antibody creation.
Book value capitalization of the company, segment and market as a whole
VCNX - Book value capitalization of the company VCNX
Vaccinex is a clinical-stage biopharmaceutical company. Its book value represents its equity. The chart below visualizes its financial resources. Its decline reflects the company's spending on expensive research in oncology and neurodegenerative diseases.
VCNX - Share of the company's book capitalization VCNX within the market segment - Oncology immuno-therapy
Vaccinex is a clinical-stage biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. Its value lies in its scientific platform. Its share of tangible assets will be minimal, which is typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Oncology immuno-therapy
Below you can see the overall book value of the biotech sector. Compared to this, Vaccinex, which is developing antibody-based therapies, looks like a "lightweight." Its value lies in its scientific platform and patents, not in its large manufacturing facilities, which is typical of a company focused on innovation.
Book value of all companies included in the broad market index - GURU.Markets
Vaccinex is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. Its assets are not drugs, but rather a scientific platform and a development portfolio. The company's balance sheet is the value of the "library of keys" from which they are trying to select the right one to treat the most complex real-world diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - VCNX
Vaccinex's balance sheet consists of its cash and patents. A market capitalization close to this cash value shows that investors place almost no value on its scientific developments. A graph of MvsBCap_Co ≈ 1 indicates the company's valuation as a "cash pit" with a small, free option to achieve a scientific miracle.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Vaccinex is a biotech company developing antibody-based therapies for the treatment of cancer and neurodegenerative diseases. Its value lies in its scientific platform. The chart shows a speculative estimate of its potential, which depends on news about the progress of clinical trials.
Market to book capitalization ratio for the market as a whole
Vaccinex develops immunotherapeutic drugs to combat cancer and neurodegenerative diseases. Like many biotech companies, its value in the eyes of investors is determined not by its current assets, but by the potential of its scientific developments. This metric reflects the premium the market is willing to pay for the hope of a future cure over and above the value of its laboratories.
Debts of the company, segment and market as a whole
VCNX - Company debts VCNX
Vaccinex, Inc., a clinical-stage biotech, uses debt to finance its research in oncology and neurodegenerative diseases. This chart shows how the company raises capital to test its scientific hypotheses through expensive clinical trials. In this field, debt is an investment in a potential scientific breakthrough.
Market segment debts - Oncology immuno-therapy
Vaccinex is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. While in clinical trials, the company is entirely dependent on external funding. This chart shows how the company manages its capital to advance its innovative, yet capital-intensive, scientific platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio VCNX
Vaccinex is a company working in the field of immuno-oncology. Its financial model is based on the expectation of a breakthrough in cancer treatment. This chart shows its reliance on debt and investor funds. It indicates high risk: the company is betting that its scientific developments will ultimately recoup all its investments.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Vaccinex is a clinical-stage biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. Funding a wide range of research requires capital. The chart shows how the company's debt burden relates to the market capitalization and risks of the entire innovative biotech sector.
Debt to book value of all companies in the market
Vaccinex (VCNX) is a clinical-stage biotech developing antibodies for the treatment of cancer and neurodegenerative diseases. Funding for such cutting-edge research is almost always provided through equity. This chart shows the overall market leverage, clearly illustrating the financial model of a biotech that remains debt-free until drug approval.
P/E of the company, segment and market as a whole
P/E - VCNX
For Vaccinex, Inc., a clinical-stage biotech, this chart reflects the company's belief in its scientific platform. There is no P/E ratio. The company's valuation is based on the potential of its antibodies to treat cancer and neurodegenerative diseases. Its performance is entirely dependent on clinical trial results.
P/E of the market segment - Oncology immuno-therapy
This industry metric represents the average P/E for biotech companies. For Vaccinex, which is in clinical development, it serves as a benchmark. It reflects the overall level of optimism in the sector, providing context for Vaccinex's valuation, which is betting on its unique scientific approach to treating cancer and neurodegenerative diseases.
P/E of the market as a whole
Vaccinex is a biotech company developing antibody-based therapies for cancer and neurodegenerative diseases. Its valuation depends on the success of its scientific platform. This chart shows the overall risk appetite of investors. It helps understand how the overall investment climate in the biotech sector affects Vaccinex's ability to fund its expensive research and development.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company VCNX
Vaccinex is a clinical-stage biotech company developing targeted therapies for cancer and neurodegenerative diseases. This chart shows analysts' speculative expectations. It reflects not current revenue, but the potential value of its scientific platform if key clinical trials are successful.
%20P%2FE%20VCNX&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-VCNX&v=1772542034409 "Chart of the company's future (projected) P/E VCNX")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. This chart shows average expectations for the biotech sector. VCNX's position may indicate how investors view its unique scientific platform and the potential of its lead drug candidate in clinical trials.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772542034412 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Vaccinex, Inc. is a biotech company focused on oncology and neurodegenerative diseases. Its valuation is based on the potential of future drugs. Overall market sentiment on this chart influences investor willingness to invest in risky projects with a long-term future.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772542034413 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit VCNX
Vaccinex, Inc. is a biopharmaceutical company developing therapeutic antibodies for the treatment of cancer and neurodegenerative diseases such as Huntington's disease. This chart illustrates the complex scientific work involved. Long-term losses are related to research investments, while future profits depend on the success of their key drug candidate, pepinemab.
Profit of companies in the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company using its platform to discover antibodies for the treatment of cancer and neurodegenerative diseases. Profitability in the immuno-oncology sector, as this chart shows, reflects a collective bet that the immune system can defeat cancer. For VCNX, success depends on the results of clinical trials of its innovative approaches.
Overall market profit
Vaccinex, Inc., focused on treating cancer and neurodegenerative diseases, is at the forefront of biomedical research. Its value is determined by the potential of its scientific platform. Economic cycles, illustrated by this chart, do not directly impact demand for its drugs but play a key role in the availability of funding for long-term clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company VCNX
Vaccinex is a biotech company developing targeted therapies for cancer and neurodegenerative diseases. This chart reflects analyst expectations, which are an assessment of the scientific potential of its platform. The forecast dynamics reflect the market's confidence in the success of its clinical programs.
%20profit%20of%20the%20company%20VCNX&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-VCNX&v=1772542034442 "Graph of future (projected) profit of the company VCNX")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company developing antibodies to treat cancer and neurodegenerative diseases such as Huntington's disease. Its value lies in the potential of its scientific platform. This chart shows the revenue forecast for the immuno-oncology sector, reflecting the overall investor confidence in new approaches to treating complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772542034454 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Vaccinex, Inc. is a biotech company focused on oncology and neurodegenerative diseases. Its prospects are driven by scientific advances. The economic environment, reflected in the forecast, influences the company through the availability of financing. In good times, investors are willing to take risks; in bad times, they prefer more reliable assets, making life difficult for biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772542034496 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - VCNX
Vaccinex is a clinical-stage biotech developing antibodies for the treatment of cancer and neurodegenerative diseases. It has virtually no sales revenue. The chart reflects a speculative valuation of its scientific platform. Investors are betting on the future success of clinical trials rather than current financial performance.
P/S market segment - Oncology immuno-therapy
Vaccinex, Inc. develops targeted antibodies for the treatment of cancer and neurodegenerative diseases. The chart shows the average revenue estimate in the biotech sector. It provides insight into how investors value the potential of its scientific platform for treating complex diseases compared to the industry average.
P/S of the market as a whole
Vaccinex, Inc. is a biotech company developing antibody-based therapies for the treatment of cancer and neurodegenerative diseases. Its valuation is based almost entirely on the potential of its scientific platform. The graph of average market revenue estimates clearly demonstrates the gap between the valuations of companies with real revenue and biotechs in the R&D stage.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company VCNX
Vaccinex is a clinical-stage biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. This chart is a measure of market optimism, valuing the company based on the potentially huge future revenues its drugs could generate if clinical trials are successful.
%20P%2FS%20VCNX&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-VCNX&v=1772542034563 "The graph of the company's future (projected) P/S VCNX")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. This chart shows the average estimated future sales for companies in its segment. It provides context for understanding how the market views Vaccinex's scientific platform and the commercial potential of its drugs compared to competitors' developments.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772542034564 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Vaccinex, Inc. is a biotech company whose platform targets cancer and neurodegenerative diseases. Its value is derived from the potential of its scientific developments. This overall revenue expectation schedule is irrelevant to the company. Investors are focused entirely on clinical trial data, which will determine its future.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772542034571 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales VCNX
Vaccinex is a clinical-stage biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. Revenue, if any, in this graph likely comes not from sales but from partnerships and grants. These funds are crucial for funding its cutting-edge scientific research.
Sales of companies in the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company developing targeted antibody-based therapies for the treatment of cancer and neurodegenerative diseases. Their key platform targets a protein that plays a key role in the development of these diseases. This chart shows the total revenue in the immuno-oncology sector, providing insight into the rapid growth of this cutting-edge market.
Overall market sales
Vaccinex, Inc. is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. Its development depends on successful clinical trials. The overall economic situation, reflected in this chart, influences the level of investment in the biotech sector and funding for advanced treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company VCNX
Vaccinex, Inc. is a biotechnology company developing antibodies for the treatment of cancer and neurodegenerative diseases. Its future depends on the success of clinical trials and partnerships with major pharmaceutical companies. This chart visualizes market expectations regarding the commercial potential of its scientific platform.
%20sales%20of%20the%20company%20VCNX&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-VCNX&v=1772542034598 "Schedule of future (projected) sales of the company VCNX")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotechnology company developing antibodies for the treatment of cancer and neurodegenerative diseases such as Huntington's disease. It is a cutting-edge scientific platform. This chart illustrates forecasts for the entire immuno-oncology sector. Vaccinex's future depends on the success of its drugs in clinical trials.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772542034611 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Vaccinex, Inc. is a biotech company developing antibodies to treat cancer and neurodegenerative diseases. Its long-term prospects depend on the influx of capital into research. This chart, illustrating overall economic confidence, influences investor willingness to fund the multi-year, risky clinical trials being conducted by VCNX.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772542034618 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality VCNX
Vaccinex, Inc. is a biotechnology company developing targeted antibody-based therapies for the treatment of cancer and neurodegenerative diseases. The company is in clinical trials. This chart illustrates the investment required to bring innovative drugs to market that have the potential to generate profits in the future.
Market segment marginality - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. This chart shows the average revenue in the pharmaceutical industry. As a clinical-stage company, its future ability to exceed this metric depends entirely on the success of its platform and the progress of its candidates through the clinical trials.
Market marginality as a whole
Vaccinex, Inc. is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. It is in clinical trials, meaning it has no operating profit. This gross margin chart clearly demonstrates the gap between today's revenue-generating businesses and the science-intensive companies investing in the medicine of the future.
Employees in the company, segment and market as a whole
Number of employees in the company VCNX
Vaccinex is a biotech company developing targeted antibodies for the treatment of cancer and neurodegenerative diseases. Its value lies in its scientific platform. This chart shows the size of its team of researchers and clinicians who drive its innovative programs to develop new treatments.
Share of the company's employees VCNX within the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company using its platform to discover antibodies for the treatment of cancer and neurodegenerative diseases. It's a science-intensive business where breakthroughs are achieved by small teams. This metric shows the share of specialized researchers Vaccinex has in its niche, positioning it as a center of scientific expertise.
Number of employees in the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company developing targeted antibodies for the treatment of cancer and neurodegenerative diseases. The growth of its research team, which can be seen in the graph, is a leading indicator. This increase in staffing indicates active work on several programs and progress in preclinical and clinical trials.
Number of employees in the market as a whole
Vaccinex uses its unique antibody platform to combat cancer and neurodegenerative diseases. This chart illustrates its focused R&D strategy. A small team of highly qualified scientists forms the company's core. Any expansion of this team signals the achievement of important scientific results and progression to later-stage clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company VCNX (VCNX)
Vaccinex is a biopharmaceutical company working in the field of immuno-oncology. The company's value at the clinical development stage is determined almost exclusively by its intellectual property—patented platforms and drug candidates. This metric reflects how the market values the future cash flows from these patents per scientist or employee.
%20of%20the%20company%20VCNX%20(VCNX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-VCNX-VCNX&v=1772542034672 "Chart of market capitalization per employee (in thousands of dollars) of the company VCNX (VCNX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Vaccinex, Inc. is a biotech company using its antibody platform to develop treatments for cancer and neurodegenerative diseases. Its value is determined by the potential for scientific breakthroughs. This chart shows how investors value the company's intellectual capital per scientist.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772542034682 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Vaccinex, Inc. is a clinical-stage biotechnology company developing antibodies for the treatment of cancer and neurodegenerative diseases. This chart illustrates the assessment of scientific potential. It shows how the market values the contribution of a small team of scientists to the creation of potentially breakthrough therapeutic platforms.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772542034685 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company VCNX (VCNX)
Vaccinex is a clinical-stage biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases. The company is not commercially profitable. This chart shows the net loss (R&D costs) per scientist. It's a venture bet on a future technology.
%20Chart%20VCNX%20(VCNX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-VCNX-VCNX&v=1772542034694 "Company Profit Per Employee (in thousands of dollars) Chart VCNX (VCNX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Vaccinex is a biotech company developing antibodies for the treatment of cancer and neurodegenerative diseases using its ActivMAb platform. This chart shows the loss per employee during clinical trials. It serves as a benchmark for assessing how intensively the company invests in its scientists to advance its drug candidates compared to other biotech companies.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772542034695 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Vaccinex is a clinical-stage biotech company developing a platform for discovering antibodies targeting cancer and neurodegenerative diseases. VCNX has no commercial products. This chart shows negative profit (loss) per scientist, reflecting the R&D investment phase of drug discovery.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772542034697 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee VCNX (VCNX)
Vaccinex, Inc. is a biotech company working in the field of immuno-oncology. This graph shows the points at which its research and development efforts begin to generate revenue. Increases in revenue per employee are typically driven by licensing agreements or partnerships with large pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-VCNX-VCNX&v=1772542034706 "Sales chart per company employee VCNX (VCNX)")
Sales per employee in the market segment - Oncology immuno-therapy
Vaccinex (VCNX) is a clinical-stage biotech developing targeted antibodies for the treatment of cancer and neurodegenerative diseases. The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity would be zero, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
Vaccinex is a biotech company developing immuno-oncology drugs. Like many companies in the R&D stage, this metric reflects investments in the future. A team of scientists is working on developing a platform, and this metric will only increase if clinical trials are successful and their research is commercialized.
Short shares by company, segment and market as a whole
Shares shorted by company VCNX (VCNX)
Vaccinex (VCNX) is a biotech company developing antibodies to treat cancer and neurodegenerative diseases (such as Huntington's disease). This metric measures skepticism. Bears doubt the success of their clinical trials. The high volume of bets against the company is typical for an early-stage biotech with a risky but breakthrough technology.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-VCNX-VCNX&v=1772542034729 "Short Shares Chart for the Company VCNX (VCNX)")
Shares shorted by market segment - Oncology immuno-therapy
Vaccinex (VCNX) is a biopharmaceutical company developing immunotherapy treatments for cancer and neurodegenerative diseases. It's at the cutting edge of science. This indicator measures the total number of short bets across the entire oncology-focused biotech sector. High readings indicate general investor skepticism about this complex and capital-intensive area of research.
Shares shorted by the overall market
Vaccinex is a clinical-stage biotech developing cancer drugs. This chart measures overall fear. When investors are pessimistic, they are unprepared for the binary risks of clinical trials. They sell off VCNX shares, fearing the company will not have enough capital to complete R&D amid market panic and expensive financing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator VCNX (VCNX)
Vaccinex (VCNX) is a biotech company whose platform (SEMA) is used to discover and develop antibodies, including for the treatment of cancer and neurodegenerative diseases. This chart measures the strength of speculative moves. It shows when the stock is "overheated" (above 70) on partnership news or "oversold" (below 30) due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-VCNX-VCNX&v=1772542034756 "RSI 14 indicator chart for the company's stock VCNX (VCNX)")
RSI 14 Market Segment - Oncology immuno-therapy
Vaccinex is a "biotech" company, an antibody "engineer." Their *platform* (ActivMAb) *discovers* *new* antibodies for the treatment of *cancer* and *neurodegenerative* diseases. The "Oncology immunotherapy" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It helps us understand: is VCNX's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Vaccinex (VCNX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VCNX (VCNX)
Vaccinex is a biotech company developing antibody-based drugs (pepinemab) for the treatment of cancer and neurodegenerative diseases (Alzheimer's, Huntington's). This chart shows the average 12-month forecast of analysts, representing their collective speculative bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VCNX-VCNX&v=1772542034785 "A chart showing analyst consensus forecasts for the expected stock price. VCNX (VCNX)")
The difference between the consensus estimate and the actual stock price VCNX (VCNX)
Vaccinex (VCNX) is a biotech company developing drugs (antibodies) for the treatment of cancer and neurodegenerative diseases (Alzheimer's, Parkinson's). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and the forecast, reflecting their "venture capital" valuation of this sophisticated R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VCNX-VCNX&v=1772542034794 "A chart showing the difference between the consensus forecast and the actual stock price. VCNX (VCNX)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Vaccinex (VCNX) is a biotech company developing antibodies to treat cancer and neurodegenerative diseases (Alzheimer's). This is an R&D bet. This chart shows analysts' overall expectations for the immunotherapy sector. It reflects whether experts believe this risky R&D platform will succeed.
Analysts' consensus forecast for the overall market share price
Vaccinex (VCNX) is an antibody "factory." It's a biotech company with an R&D platform (ActivMAb) for discovering new antibody drugs. They are developing drugs for cancer and neuroscience. This chart shows the overall risk appetite. It reflects the level of investor confidence in the R&D budgets of "big pharma," which is a potential partner for VCNX.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index VCNX
Vaccinex develops targeted therapies using its antibody platform to treat oncology and neurodegenerative diseases. Their lead candidate targets a complex protein. This chart is a comprehensive barometer that attempts to assess the scientific potential of their platform, the risks associated with clinical trials in complex areas (cancer, Alzheimer's disease), and their financial position.
AKIMA Market Segment Index - Oncology immuno-therapy
Vaccinex (VCNX) is an immuno-oncology company. They develop targeted antibodies that aim to help the immune system fight cancer and also research neurodegenerative diseases. This chart compares their composite index to the immunotherapy sector average.
The AKIM Index for the overall market
Vaccinex is a biotech company developing antibodies (pepinemab) for the treatment of neurodegenerative diseases and cancer. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop critical to the survival of this micro-cap research company.
